Dr. Robert L. Dubin, MD
Endocrinology & Diabetes (Endocrinology, Diabetes & Metabolism Physician)
At a glance
- In the NPI registry since
- 2006
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Endocrinology, Diabetes & Metabolism Physician primary
FL license ME88538
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 425 | 269 |
| Hemoglobin a1c level | 304 | 171 |
| Insertion of needle into vein for collection of blood sample | 225 | 148 |
| Blood test, comprehensive group of blood chemicals | 192 | 134 |
| Established patient office or other outpatient visit, 40-54 minutes | 165 | 133 |
| Blood test, thyroid stimulating hormone (tsh) | 132 | 93 |
| Thyroxine (thyroid chemical), free | 121 | 83 |
| Blood test, lipids (cholesterol and triglycerides) | 90 | 74 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 57 | 48 |
| Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | 56 | 25 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Levothyroxine Sodium Other prescribers in Venice, FL | 55 |
| Jardiance (empagliflozin) Other prescribers in Venice, FL | 34 |
| Metformin Hcl Er (metformin hcl) Other prescribers in Venice, FL | 28 |
| Ozempic (semaglutide) Other prescribers in Venice, FL | 24 |
| Metformin Hcl Other prescribers in Venice, FL | 21 |
| Synthroid (levothyroxine sodium) Other prescribers in Venice, FL | 20 |
| Tresiba Flextouch U-100 (insulin degludec) Other prescribers in Venice, FL | 19 |
| Tresiba Flextouch U-200 (insulin degludec) Other prescribers in Venice, FL | 17 |
| Lantus Solostar (insulin glargine,hum.rec.anlog) Other prescribers in Venice, FL | 16 |
| Novolog Flexpen (insulin aspart) Other prescribers in Venice, FL | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 17 payments worth $17,941 in total to this clinician.
| Eli Lilly and Company | $11,219 |
|---|---|
| Lilly USA, LLC | $6,600 |
| Novo Nordisk Inc | $122 |
| Food and Beverage | $10,126 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $6,600 |
| Travel and Lodging | $1,215 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Lilly USA, LLC Jul 18, 2025 | Compensation for services other than consulting (speaking, faculty) ZEPBOUND · Obesity | $3,025 |
| Lilly USA, LLC Oct 14, 2025 | Compensation for services other than consulting (speaking, faculty) | $2,200 |
| Lilly USA, LLC Oct 14, 2025 | Compensation for services other than consulting (speaking, faculty) | $1,375 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, LA · in-kind | $441 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind | $269 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind | $269 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS | $90.00 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind | $46.06 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind | $45.73 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS | $42.00 |
All 15 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Lilly USA, LLC Oct 14, 2025 | Compensation for services other than consulting (speaking, faculty) | $2,200 |
| Lilly USA, LLC Oct 14, 2025 | Compensation for services other than consulting (speaking, faculty) | $1,375 |
| Lilly USA, LLC Jul 18, 2025 | Compensation for services other than consulting (speaking, faculty) ZEPBOUND · Obesity | $3,025 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, LA · in-kind | $441 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind | $269 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind | $269 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS | $90.00 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind | $46.06 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind | $45.73 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS | $42.00 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS | $6.96 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind | $1.99 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS | $1.70 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS | $1.49 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS | $0.35 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $161,906 in research payments for these studies, mostly to the institutions running them.
- A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
Eli Lilly and Company · Active, not recruiting · NCT05869903 - A phase 2A randomized doubleblind sponsoropen placebocontrolled parallel group doseranging study of PF07976016 to assess safety and efficacy in adult participants with obesity
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.